The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

Inclusion Criteria: * Healthy infants, both sexes, between 6 and 12 weeks of age on the day of screening and enrollment * Subject born at full term of pregnancy (greater or equal to 37 weeks) and Birth weight ≥2500 grams * Weight ≥ 3,300 grams at the time of screeningSubject with good health as determined by the medical history, physical examination and clinical judgment of the Investigator * Parent / legal representative can understand and be able to comply with the requirements of the protocol * Subjects born to mothers who are seronegative to HIV, HBV and HCV through a blood test or maternity record. * Parent / legal representative is willing to voluntarily sign the consent form for the participant Exclusion Criteria: * History of diphtheria, tetanus, pertussis, hepatitis B, or Hib infections (confirmed either clinically, serologically or microbiologically) * Fever (temperature ≥37.50C) or hypothermia (≤35.50C) or acute illness / infection that requires treatment. * Previous vaccination against diphtheria, tetanus, pertussis and Haemophilus influenzae type b diseases. * Known allergy to any component of the vaccine; * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination. * Being treated with anticoagulants or at high risk of bleeding. * A family history of SIDS (sudden infant death syndrome) * Have received any blood products, corticosteroids, cytotoxic drugs, immunosuppressive therapy, radiation therapy in the last 4 weeks. * Have participated in another clinical trial within 30 days prior to the study vaccination or may participate in the course of the study. * A family history of congenital or hereditary immunodeficiency. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Major congenital defects. * History of any neurological disorders or seizures